Indoco Remedies has surged 14% to Rs 187 on BSE after the pharmaceuticals company said it has received a nod from the US Food and Drug Administration (FDA) for two of its facilities in Goa.
The Company has received Establishment Inspection Report (EIR) approving the Company's sterile manufacturing facility (Plant II) and solid dosage manufacturing facility (Plant III) located in Verna, Goa, Indoco Remedies said in a statement.
The company derived 35% of its revenues from exports in 2013-14.
The stock opened at Rs 179 and touched a record high of Rs 197 on BSE. The counter has seen huge trading activity with a combined 782,000 shares changing hands in first 20 minutes of trading on BSE and NSE.
The Company has received Establishment Inspection Report (EIR) approving the Company's sterile manufacturing facility (Plant II) and solid dosage manufacturing facility (Plant III) located in Verna, Goa, Indoco Remedies said in a statement.
The company derived 35% of its revenues from exports in 2013-14.
The stock opened at Rs 179 and touched a record high of Rs 197 on BSE. The counter has seen huge trading activity with a combined 782,000 shares changing hands in first 20 minutes of trading on BSE and NSE.
